McCormick Q2 Results Show Modest Gains Amid Deal Overhang; Outlook Unchanged

What happened

McCormick reported Q2 results characterized by continued organic volume weakness, though headline growth was boosted by acquisitions and FX. The company reaffirmed its FY2026 adjusted EPS guidance of $3.05-$3.13, implying limited earnings power improvement absent deal closure. The Unilever Foods Reverse Morris Trust remains the dominant catalyst, but no material progress on S-4 filing, shareholder vote timing, or permanent financing was disclosed. Competitive promotional activity, particularly in U.S. mustard, persists as a risk to pricing and volume, and Flavor Solutions continues to face large customer softness. Management's narrative of 'strong performance' should be viewed skeptically given that organic sales growth remains tepid and the stock's valuation is heavily dependent on deal execution rather than underlying business momentum.

Implication

While the underlying business shows resilience with margin improvement, the risk/reward is skewed unfavorably until the Unilever deal de-risks through antitrust clarity and financing. Investors should remain on the sidelines, targeting an entry near $45, or consider reducing if divestiture language emerges.

Thesis delta

The Q2 release changes nothing in the thesis. Organic volume is still negative, and deal execution is still the sole swing factor. If volume trends improve or IEEPA tariff refunds are recognized, the bull case could emerge, but for now, the WAIT rating remains intact.